Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Shannon

Showing results (231-240 of 245) with videos related to

Pageof 25
Sort By:
Nature Medicine|September 22, 2022
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiomeRebecca C Simpson, Erin R Shanahan, Marcel Batten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
JAMA Dermatology|April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous MelanomaSerigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 25

Showing results (231-240 of 245) with videos related to

Sort By:
Pageof 25
Nature Medicine|September 22, 2022
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiomeRebecca C Simpson, Erin R Shanahan, Marcel Batten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
JAMA Dermatology|April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous MelanomaSerigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 25